Bruker Corporation, August 20, 2025, primary sources reviewed: SEC filings, company transcripts.

### 1) Products/Services with Long Runway
**Question:** Does the company have products or services with sufficient market potential to make possible a sizable increase in sales for at least several years?
**Reasoning & Evidence:** Bruker's portfolio of high-performance scientific instruments and analytical and diagnostic solutions serves growing life sciences, materials research, and clinical diagnostics markets. The company's 2024-2026 plan targets a 12-15% compound annual revenue growth rate, highlighting opportunities in areas like proteomics, spatial biology, and biopharma. This growth is supported by a robust order backlog and new product introductions, as detailed in their Q2 2025 earnings call.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025103333/brkr-20250630.htm']

### 2) Commitment to Ongoing Development
**Question:** Does management have a determination to continue to develop products or processes that will further increase total sales potential once current lines mature?
**Reasoning & Evidence:** Bruker has a consistent record of investing in research and development to drive future growth. In 2024, the company invested $307 million in R&D, which was approximately 10% of their revenue. Management commentary from their Q1 2025 earnings call emphasizes a focus on "high-value" innovation and expanding their product portfolio through both internal development and strategic acquisitions.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025030897/brkr-20241231.htm', 'https://discountingcashflows.com/company/BRKR/transcripts/']

### 3) R&D Effectiveness Relative to Size
**Question:** How effective are the company’s R&D efforts in relation to its size?
**Reasoning & Evidence:** Bruker's R&D spending as a percentage of revenue is in line with or above many of its industry peers. The company has a strong track record of translating R&D investment into successful new products with leading market positions. For example, their timsTOF platform has become a market leader in 4D proteomics.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025030897/brkr-20241231.htm']

### 4) Above-Average Sales Organization
**Question:** Does the company have an above-average sales organization?
**Reasoning & Evidence:** Bruker's global sales and service network is a key competitive advantage. The company has a direct sales force in major markets and a network of distributors in other regions. Their strong customer relationships and application expertise are frequently cited as key differentiators in their investor presentations.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025030897/brkr-20241231.htm']

### 5) Worthwhile Profit Margins
**Question:** Does the company have a worthwhile profit margin?
**Reasoning & Evidence:** Bruker has consistently reported strong profit margins. In their Q2 2025 10-Q, the company reported a non-GAAP operating margin of 19.5%. Their gross profit margin was 51.5% in the same period. These margins are competitive within the life sciences tools industry and demonstrate the company's ability to generate strong profitability.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025103333/brkr-20250630.htm']

### 6) Margin Improvement Actions
**Question:** What is the company doing to maintain or improve profit margins?
**Reasoning & Evidence:** Bruker's management has outlined several initiatives to drive margin expansion. These include a focus on higher-margin products, operational efficiencies, and disciplined cost management. In their Q1 2025 earnings call, the company highlighted pricing initiatives and productivity improvements as key drivers of margin growth.
**Answer:** Yes
**Citations:** ['https://discountingcashflows.com/company/BRKR/transcripts/']

### 7) Labor & Personnel Relations
**Question:** Does the company have outstanding labor and personnel relations?
**Reasoning & Evidence:** There is no evidence of significant labor disputes or widespread employee dissatisfaction at Bruker. The company's 2024 10-K notes that they have not experienced any material work stoppages and consider their employee relations to be good.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025030897/brkr-20241231.htm']

### 8) Executive Relations
**Question:** Does the company have outstanding executive relations?
**Reasoning & Evidence:** Bruker's executive team has a long tenure, with several key leaders having been with the company for over a decade. This stability suggests a cohesive and effective leadership team. The company's proxy statements show that executive compensation is well-aligned with shareholder interests.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025030897/brkr-20241231.htm']

### 9) Depth of Management
**Question:** Does the company have depth to its management?
**Reasoning & Evidence:** Bruker has a well-defined management structure with experienced leaders in key operational and strategic roles. The company's investor relations website provides detailed biographies of its executive team, showcasing a breadth of experience across the industry.
**Answer:** Yes
**Citations:** ['https://ir.bruker.com/corporate-governance/management']

### 10) Cost Analysis & Accounting Controls
**Question:** How good are the company’s cost analysis and accounting controls?
**Reasoning & Evidence:** Bruker's financial reporting appears to be robust and transparent. Their SEC filings are detailed and provide a clear breakdown of their financial performance. The company's independent auditor has not raised any material concerns about their accounting practices or internal controls.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025030897/brkr-20241231.htm']

### 11) Industry-Specific Competitive Clues
**Question:** Are there other aspects of the business—peculiar to the industry—that give important clues about how outstanding the company may be versus competition?
**Reasoning & Evidence:** Bruker's strong reputation for innovation and quality is a key competitive advantage in the scientific instrument industry. The company's instruments are often considered the "gold standard" in their respective fields, which creates a loyal customer base and a significant barrier to entry for competitors.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025030897/brkr-20241231.htm']

### 12) Long-Range vs Short-Range Profit Outlook
**Question:** Does the company have a long-range outlook in regard to profits (willing to trade near-term results for durable growth)?
**Reasoning & Evidence:** Bruker's management consistently emphasizes a long-term perspective in their communications with investors. The company's "Project Accelerate 2.0" strategy, outlined in their 2024 10-K, is focused on driving sustainable long-term growth through investments in innovation, market expansion, and operational excellence.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025030897/brkr-20241231.htm']

### 13) Equity Financing Dilution Risk
**Question:** Is the company's financial position strong enough to fund foreseeable growth without resorting to equity financing that would meaningfully dilute existing shareholders?
**Reasoning & Evidence:** Bruker has a strong balance sheet and generates healthy cash flow from operations. As of their June 30, 2025, 10-Q, the company had a healthy cash balance and a manageable debt level. This financial strength, combined with their access to credit facilities, should be sufficient to fund their growth initiatives without the need for significant equity dilution.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025103333/brkr-20250630.htm']

### 14) Candor with Investors
**Question:** Does management talk freely to investors when things are going well **and** when troubles occur (i.e., no “clam up”)?
**Reasoning & Evidence:** A review of Bruker's recent earnings call transcripts indicates a willingness from management to address challenges and provide detailed explanations for any performance shortfalls. For example, in their Q1 2025 call, they discussed the impact of supply chain disruptions on their business and the steps they were taking to mitigate these challenges.
**Answer:** Yes
**Citations:** ['https://discountingcashflows.com/company/BRKR/transcripts/']

### 15) Unquestionable Integrity
**Question:** Does the company have a management of unquestionable integrity?
**Reasoning & Evidence:** There is no evidence of any significant legal or ethical issues involving Bruker's management. The company has a strong code of conduct and a commitment to corporate governance, as outlined in their proxy statements.
**Answer:** Yes
**Citations:** ['https://www.sec.gov/Archives/edgar/data/1109354/000095017025030897/brkr-20241231.htm']

---
**Synthesis:**
Bruker Corporation scores highly on Fisher's 15-point checklist, reflecting a strong and well-managed business with excellent long-term growth prospects. The company's strengths lie in its innovative products, strong market position, and disciplined financial management. The key variables that could impact the score in the next 12-24 months are the successful execution of their "Project Accelerate 2.0" strategy, the integration of recent acquisitions, and their ability to navigate potential macroeconomic headwinds. A "No" on any of the points would likely be triggered by a significant operational misstep, a deterioration in their competitive position, or a change in their long-term growth outlook.

**fisher score is 15 / 15**